PC Reviewed: 9/8/20   **Status: _____**   **Priority: 2**
SC Reviewed: _____   **Status: _____**   **Priority: ____**

1.a. Full Title: When are representative samples necessary for generalizability? A comparison between ADNI and ARIC

  b. Abbreviated Title (Length 26 characters): Sample representativeness

2. Writing Group:
    Writing group members:

Kan Z. Gianattasio (first); Jingkai Wei; Erin Bennett; Megha Mehrotra; M. Maria Glymour; Thomas Mosley; Rebecca Gottesman; Elizabeth Stuart; Michael E. Griswold; David Couper; Melinda C. Power (last)

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. _KZG____ **[please confirm with your initials electronically or in writing]**

F**irst author**: Kan Gianattasio
Address: 950 New Hampshire Ave NW, 5th Floor, Washington DC 20052

      Phone: 202-994-2572   Fax:
      E-mail: kzhang0316@gwu.edu

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

  Name: Melinda C. Power
Address: 950 New Hampshire Ave NW, 5th Floor, Washington DC 20052

      Phone: 202-994-7778   Fax:
      E-mail: power@gwu.edu

3. Timeline:
October 2019 – August 2020: Examine differences in associations between ARIC and ADNI; write manuscript
August 2020 – September 2021: Explore use of transportability algorithms to generalize findings from ADNI and ARIC; write manuscript

4. Rationale:

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal study that collects high quality imaging, biomarker, genetic, and clinical data from participants recruited from over 60 sites in the US and Canada.[1] Its data is shared publicly, and has allowed researchers to make important progress on identifying biomarker changes associated with early stage Alzheimer's disease and its disease progression and risk factors for these biomarker changes and clinical outcomes.[2,3] However, because ADNI recruitment procedures resulted in a highly-selected sample that is predominantly white and disproportionately well-educated,[1,4] certain types of estimated associations from ADNI may not be generalizable to the larger US population. It is therefore important to understand when ADNI findings are likely to be widely generalizable without adjustment, when adjustment for observed characteristics is sufficient, and when representative samples may be more necessary to make broad inferences.

The Atherosclerosis Risk in Communities (ARIC) study collects similar cognitive and imaging measures as similar to those in ADNI. Importantly, because ARIC participants were selected randomly from across four US communities, it is relatively more representative of the general population than is the ADNI sample. Thus, ARIC provides an opportunity against which ADNI can be evaluated for external validity. Specifically, comparing various associations (between sociodemographic factors, cognitive outcomes, and imaging outcomes) in ADNI vs. in ARIC will provide insight into which types of associations between variables can be directly generalized from ADNI to the four ARIC communities. For a subset of associations that differ significantly between ADNI and ARIC, we will explore whether use of transportability algorithms allow for improved generalizability between the two cohorts.

5. Main Hypothesis/Study Questions:

How do the associations between risk factors and imaging outcomes differ between ADNI and ARIC?

Does use of transportability algorithms allow for improved generalizability of associations between ADNI and ARIC?

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary

of data analysis, and any anticipated methodologic limitations or challenges if present).

Study Design:
Cross-sectional analysis using ARIC Visit 5 data and ADNI baseline and screening data from ADNI.

Inclusion/Exclusion:

All primary analyses in ARIC will be limited to white and Black participants at Visit 5.

For analyses involving PET amyloid-β data, all ARIC Visit 5 participants of the ARIC-PET Amyloid Imaging Study without dementia and with non-missing data on age, gender, education and race.

For analyses involving MRI data, all ARIC Visit 5 participants with MRI and with non-missing data on age, gender, education, race, and dementia status.

Similar exclusion/inclusion criteria will be applied to the ADNI screening/baseline visit data.

Independent variables:

- Age
- Gender
- Education
- Race
- Dementia status (dementia / no dementia)
- Marital status
- Blood pressure
- History of hypertension
- Blood cholesterol and triglycerides
- Functional status
- ApoE4

Dependent variables:

- Cognitive performance (MMSE, word fluency, animal fluency, Boston naming)
- amyloid-β
- AD signature region volume
- Frontal lobe volume
- Temporal lobe volume

Hypothesized confounders

Age, gender, education, cognitive status (dementia, no dementia)

Statistical Analyses:

Part 1 – comparison of associations between ARIC and ADNI
We have confirmed close comparability of the variables above in ARIC and ADNI. We will pool the ARIC and ADNI datasets, and run unadjusted and adjusted linear and logistic regressions to examine associations between each of the independent variables with each of the dependent variables. Note that for the purposes of this paper, we are interested only in comparing estimated associations across the datasets, and not in estimating causal effects. All models will include an indicator for dataset (1=ADNI, 0=ARIC) and its interaction with the independent variable of interest; models will also include age, gender, education, race, dementia status, and each of their interactions with dataset indicator. We will also examine associations between the MRI outcomes (AD signature region volume, frontal lobe volume, temporal lobe volume) and PET outcome (amyloid-β), similarly including an indicator for dataset and its interaction with the predictor of interest, as well as age, gender, and education. Similarity and differences in findings will be summarized in tables and figures. We will examine whether findings are sensitive to the homogeneity of sample participants (by limiting analyses to increasing homogenous samples defined by race and cognitive status), as well as to changes in sample selection by conducting complete-case analyses. Sensitivity analyses will incorporate ARIC MRI sampling weights.

Part 2 – assessing use of transportability algorithms to generalize associations between cohorts
Analyses completed for Part 1 indicate a substantial number of associations, greater than would be expected by chance, differ across ARIC and ADNI. If this is driven by an imbalance in effect modifiers, it may be possible to use transport algorithms to use data from one sample (e.g. ADNI) to estimate the association present in the second sample (ARIC). Therefore, for a subset of associations that differ significantly between ARIC and ADNI, we will examine the transportability of estimated associations from ADNI to ARIC using statistical techniques developed for this purpose. Specifically, we will apply commonly used selection-based estimators (e.g., stratification, inverse-probability weighting, standardization/g-formula, or doubly-robust estimators (e.g. augmented inverse-probability weighted, doubly-robust weighted least squares, TMLE)) to transport association estimates from ADNI to the ARIC sample, and compare the transported estimates to those directly estimated from ARIC. As previously, we will examine whether findings are sensitive to variations in sample selection. If we are unable to produce comparable estimates using transport estimators, we will explore whether an imbalanced distribution of unknown and/or unmeasurable modifiers or positivity violations in distribution of modifiers drives this finding. These analyses will provide an exploration of whether transport algorithms can feasibly be used to generalize findings from highly selected clinical samples to broader populations of interest.

7.a. Will the data be used for non-CVD analysis in this manuscript?   ___X_ Yes ____ No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES_DNA = "CVD Research" would be used?   __X__ Yes ____ No
(This file ICTDER has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

**8.a. Will the DNA data be used in this manuscript?
___X_ Yes ____ No**

**8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = "No use/storage DNA"?
_X___ Yes ____ No**

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://www.cscc.unc.edu/ARIC/search.php

___X___ Yes   _____ No

10. What are the most related manuscript proposals in ARIC (authors are encouraged to contact lead authors of these proposals for comments on the new proposal or collaboration)?

11.a. Is this manuscript proposal associated with any ARIC ancillary studies or use any ancillary study data?   ___X_ Yes ____ No

11.b. If yes, is the proposal
__X_ A. primarily the result of an ancillary study (list number* 1999.01, 2009.29 and 2017.01)
___   B. primarily based on ARIC data with ancillary data playing a minor role (usually control variables; list number(s)* _____ _____ _____)

*ancillary studies are listed by number at http://www.cscc.unc.edu/aric/forms/

12a. Manuscript preparation is expected to be completed in one to three years. If a manuscript is not submitted for ARIC review at the end of the 3-years from the date of the approval, the manuscript proposal will expire.

12b. The NIH instituted a Public Access Policy in April, 2008 which ensures that the public has access to the published results of NIH funded research. It is **your responsibility to upload manuscripts to PUBMED Central** whenever the journal does not and be in compliance with this policy. Four files about the public access policy from http://publicaccess.nih.gov/ are posted in http://www.cscc.unc.edu/aric/index.php, under Publications, Policies & Forms. http://publicaccess.nih.gov/submit_process_journals.htm shows you which journals automatically upload articles to Pubmed central.

References

1.	Alzheimer's Disease Neuroimaging Initiative. Study Design. Alzheimer's Disease Neuroimaging Initiative. http://adni.loni.usc.edu/study-design/. Published 2017.
2.	Veitch DP, Weiner MW, Aisen PS, et al. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's Dement*. 2019;15(1):106-152. doi:10.1016/j.jalz.2018.08.005
3.	Weiner MW, Veitch DP, Aisen PS, et al. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. *Alzheimer's Dement*. 2017;13(4):e1-e85. doi:10.1016/j.jalz.2016.11.007
4.	Donohue MC. Demographics. Alzheimer's Disease Neuroimaging Initiative. http://adni.loni.usc.edu/wp-content/uploads/2012/08/ADNI_Enroll_Demographics.pdf. Published 2008.